NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
This is a phase I/II study of highly selected donor lymphocyte infusions in patients
 undergoing HLA-haploidentical hemopoietic stem cell transplantation. Patients will be offered
 "pre-emptive" NK-DLI early after HSCT.

 Three schedules of NK-cell infusion will be studied: Basel patients (adult and pediatric)
 will receive NK-DLI on days +40 and +100 (pre-emptive-late); Frankfurt patients (pediatric)
 will receive NK-DLI on days +3, +40, and +100 (pre-emptive early). Patients not receiving
 pre-emptive NK-DLI with loss in donor chimerism or with evidence of minimal residual disease
 will be offered "therapeutic" NK-DLI.
Inclusion Criteria:

 -  Patients with acute/chronic leukemia, myelodysplastic syndrome, lymphoid neoplasia,
 solid tumor or bone marrow failure syndrome

 -  signed informed consent of the patient (or his/her legal representative)

 Exclusion Criteria:

 -  Patients with graft failure

 -  Patients with any grade of active acute of chronic graft-versus-host disease (GvHD)